Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Accord Healthcare Limited Sage house, 319, Pinner road North Harrow Middlesex HA1 4HF, United Kingdom
Capecitabine Accord 150 mg film-coated tablets.
Capecitabine Accord 300 mg film-coated tablets.
Capecitabine Accord 500 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Capecitabine Accord 150 mg film-coated tablets: The film-coated tablets are light peach colored, oblong shaped, biconvex, 11.4 mm in length and 5.3 mm in width, debossed with ‘150’ on one side and plain on other side. Capecitabine Accord 300 mg film-coated tablets: The film-coated tablets are white to off white, oblong shaped, biconvex, 14.6 mm in length and 6.7 mm in width, debossed with ‘300’ on one side and plain on other side. Capecitabine Accord 500 mg film-coated tablets: The film-coated tablets are peach colored, oblong shaped, biconvex, 15.9 mm in length and 8.4 mm in width, debossed with ‘500’ on one side and plain on other side. |
Capecitabine Accord 150 mg film-coated tablets: Each film-coated tablet contains 150 mg of capecitabine.
Capecitabine Accord 300 mg film-coated tablets: Each film-coated tablet contains 300 mg of capecitabine.
Capecitabine Accord 500 mg film-coated tablets: Each film-coated tablet contains 500 mg of capecitabine.
Excipient with known effect:
Capecitabine Accord 150 mg film-coated tablets: Each film-coated tablet contains 7 mg anhydrous lactose.
Capecitabine Accord 300 mg film-coated tablets: Each film-coated tablet contains 15 mg anhydrous lactose
Capecitabine Accord 500 mg film-coated tablets: Each film-coated tablet contains 25 mg anhydrous lactose
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Capecitabine |
Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-fluorouracil (5-FU). There is evidence that the metabolism of 5-FU in the anabolic pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, thereby interfering with the synthesis of deoxyribonucleic acid (DNA). The incorporation of 5-FU also leads to inhibition of RNA and protein synthesis. |
| List of Excipients |
|---|
Capecitabine Accord 150 mg and 500 mg film-coated tabletsTablet core: Anhydrous lactose Tablet coating: Hypromellose (6cps) Capecitabine Accord 300 mg film-coated tabletsTablet core: Anhydrous lactose Tablet coating: Hypromellose (6cps) |
Aluminium/aluminium or PVC/PVdC/Aluminium blister containing 30, 60 or 120 film-coated tablets. Each pack contains 30, 60 or 120 film-coated tablets.
PVC/PVdC/Aluminium perforated unit dose blister containing 30, 60 or 120 film-coated tablets. Each pack contains 30 × 1, 60 × 1 or 120 × 1 film-coated tablets.
Not all pack sizes may be marketed.
Accord Healthcare Limited Sage house, 319, Pinner road North Harrow Middlesex HA1 4HF, United Kingdom
EU/1/12/762/001-003
EU/1/12/762/004-006
EU/1/12/762/019-021
EU/1/12/762/007-009
EU/1/12/762/010-012
EU/1/12/762/022-024
EU/1/12/762/013-015
EU/1/12/762/016-018
EU/1/12/762/025-027
Date of first authorisation: 20 April 2012
Date of latest renewal: 09th January 2017
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
